Objective:

To develop a self-amplifying RNA (saRNA) therapy for supporting heart recovery post-myocardial infarction.

Key Findings:

• A single injection produced the hormone for over 4 weeks.
• Improved cardiac function, reduced infarct size, and less fibrosis were observed in preclinical models.
• The therapy was effective even in models with diabetes and atherosclerosis.

Interpretation:

The saRNA therapy may enhance the heart's natural healing processes and provide prolonged support after injury.

Limitations:

• Further studies on safety, timing, and dosing are needed before human trials.

Conclusion:

The approach offers a promising, less invasive alternative for cardiac recovery, potentially changing patient recovery trajectories.